Asenapine vs Loxapine (Adasuve)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Asenapine

Marketed by AbbVie and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00212784 · Phase 3 · completed

This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.

Reported efficacy

Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)

Result source: NCT00212771

Loxapine (Adasuve)

Marketed by Lee's Pharmaceutical and partners

Phase 3 in Schizophreniasmall molecule
Reliable signal

NCT00628589 · Phase 3 · completed

The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).

Reported efficacy

Change in PANSS-EC From Baseline (Baseline and 2 hours): Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92) (met)

Result source: NCT00628589

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsenapineLoxapine (Adasuve)
PANSS total, change-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
—Not reported
CGI-S, change-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
—Not reported
PANSS response39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
—Not reported
PSP, change—Not posted · NCT00212771—Not reported
Relapse (% of patients)—Not posted · NCT00212771—Not reported

PANSS total, change

Asenapine
-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
Loxapine (Adasuve)
—Not reported

CGI-S, change

Asenapine
-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
Loxapine (Adasuve)
—Not reported

PANSS response

Asenapine
39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
Loxapine (Adasuve)
—Not reported

PSP, change

Asenapine
—Not posted · NCT00212771
Loxapine (Adasuve)
—Not reported

Relapse (% of patients)

Asenapine
—Not posted · NCT00212771
Loxapine (Adasuve)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Asenapine: 6 of 6 rows · Loxapine (Adasuve): 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAsenapineLoxapine (Adasuve)
CGI-I
responder rate · % of participants
60.1% (n=104) vs 54.7% (n=100) placebo @ 8.3wk5.0 mg BIDa,b,c,d
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
47.1% (n=96) vs 54.7% (n=100) placebo @ 8.3wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
67% (n=112) vs 35.7% (n=115) placebo @ 0.0119wk*10 mga,b,c,d
NCT00628589 · Phase 3 · monotherapy · converted to % from 75 Participants as posted
show 1 more dose
56.9% (n=116) vs 35.7% (n=115) placebo @ 0.0119wk*5 mg
NCT00628589 · Phase 3 · monotherapy · converted to % from 66 Participants as posted
CGI-I
absolute value · score
2.5 vs 3.1 placebo score @ 8wk5.0 mg BIDa,b,c,e
NCT01190254 · Phase 3 · registry result, not featured evidence
show 1 more dose
2.8 vs 3.1 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
2.1 vs 2.8 placebo score @ 0.0119wk10 mga,b,c,e
NCT00628589 · Phase 3 · monotherapy
show 1 more dose
2.3 vs 2.8 placebo score @ 0.0119wk5 mg
NCT00628589 · Phase 3 · monotherapy
Dropout rate
44.4%5 mg twice dailyf
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
16.7%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
54.8%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
1%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
35.2%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
40.1%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
50%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.9%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
17.3%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
33.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
50.4%
NCT00145496 · Phase 3 · registry result, not featured evidence
30.4%
NCT00150176 · Phase 3 · registry result, not featured evidence
15.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
67.7%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
33.3%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
25%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
2.7%10 mgf
NCT00628589 · Phase 3 · monotherapy
show 8 more results
1.7%5 mg
NCT00628589 · Phase 3 · monotherapy
2.4%10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
22.2%5 mg twice dailyf
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
22.3%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
23.6%
NCT01244828 · Phase 3 · registry result, not featured evidence
17%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
17.6%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
0%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
5.1%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
7.5%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
6.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
8.1%
NCT00174265 · Phase 3 · registry result, not featured evidence
17.2%
NCT00145496 · Phase 3 · registry result, not featured evidence
8.2%
NCT00150176 · Phase 3 · registry result, not featured evidence
7.5%
NCT00265343 · Phase 3 · registry result, not featured evidence
11.8%
NCT00156065 · Phase 3 · registry result, not featured evidence
—5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mgf
NCT00628589 · Phase 3 · monotherapy
show 8 more results
—5 mg
NCT00628589 · Phase 3 · monotherapy
—10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
—10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
Serious AEs
0%5 mg twice dailyf
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
20.4%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
4.4%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.9%
NCT01244828 · Phase 3 · registry result, not featured evidence
5.7%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
2.8%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
12.5%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
3.6%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
2.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
3.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
4.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
12.3%
NCT00145496 · Phase 3 · registry result, not featured evidence
3.1%
NCT00150176 · Phase 3 · registry result, not featured evidence
6.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
14.1%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0.9%10 mgf
NCT00628589 · Phase 3 · monotherapy
show 8 more results
0%5 mg
NCT00628589 · Phase 3 · monotherapy
2.4%10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
2.2%5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
5 mg twice dailyf
daytime drowsiness 22.2%
NCT01549041 · Phase 4 · registry result, not featured evidence
show 19 more results
10 mg daily in the evening
daytime drowsiness 0%
NCT01549041 · Phase 4 · registry result, not featured evidence
5/10 mg BID
nasopharyngitis 21.7%
schizophrenia 10.8%
somnolence 10.8%
NCT01142596 · Phase 3 · registry result, not featured evidence
5 mg BID
insomnia 15% (placebo 13.9%)
headache 8.8% (placebo 2%)
anxiety 7.1% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
2.5 mg BID
headache 10.3% (placebo 2%)
insomnia 9.3% (placebo 13.9%)
anxiety 7.2% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21%
somnolence 12.7%
weight increased 12.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
5 mg BID
akathisia 11.4% (placebo 5.2%)
hypoaesthesia oral 10.9% (placebo 3.4%)
insomnia 9.7% (placebo 12.1%)
NCT01098110 · Phase 3 · registry result, not featured evidence
10 mg BID
schizophrenia 13.8% (placebo 24.1%)
somnolence 12.2% (placebo 1.7%)
akathisia 10.5% (placebo 5.2%)
NCT01098110 · Phase 3 · registry result, not featured evidence
accidental overdose 12.5%
acne 12.5%
akathisia 12.5%
NCT01190267 · Phase 3 · registry result, not featured evidence
somnolence 14.8%
headache 6.6%
sedation 5.1%
NCT01190267 · Phase 3 · registry result, not featured evidence
5.0 mg BID
somnolence 17% (placebo 6.9%)
sedation 11.3% (placebo 2%)
insomnia 9.4% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
2.5 mg BID
somnolence 20.4% (placebo 6.9%)
dizziness 7.1% (placebo 1%)
headache 7.1% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
insomnia 10.6%
weight increased 5.9%
headache 2.4%
NCT00174265 · Phase 3 · registry result, not featured evidence
insomnia 17.6%
somnolence 14.8%
headache 13.5%
NCT00145496 · Phase 3 · registry result, not featured evidence
insomnia 20.1% (placebo 24.5%)
somnolence 16% (placebo 17.2%)
weight increased 14.4% (placebo 10.9%)
NCT00150176 · Phase 3 · registry result, not featured evidence
headache 5.2%
influenza 5.2%
schizophrenia 5.2%
NCT00265343 · Phase 3 · registry result, not featured evidence
insomnia 18.5%
headache 10.9%
parkinsonism 10.9%
NCT00156065 · Phase 3 · registry result, not featured evidence
5 mg
dystonia 66.7%
dizziness 33.3%
nausea 33.3%
NCT01206517 · Phase 1 · registry result, not featured evidence
10 mg
hypoaesthesia oral 50%
dizziness 38.9%
dysgeusia 38.9%
NCT01206517 · Phase 1 · registry result, not featured evidence
2.5 mg
sedation 33.3%
dysgeusia 16.7%
hypoaesthesia oral 16.7%
NCT01206517 · Phase 1 · registry result, not featured evidence
10 mgf
dizziness 10.6% (placebo 9.6%)
dysgeusia 10.6% (placebo 2.6%)
sedation 10.6% (placebo 9.6%)
NCT00628589 · Phase 3 · monotherapy
show 8 more results
5 mg
sedation 12.9% (placebo 9.6%)
dysgeusia 8.6% (placebo 2.6%)
dizziness 5.2% (placebo 9.6%)
NCT00628589 · Phase 3 · monotherapy
10 mg
sedation 22% (placebo 14%)
dysgeusia 17.1% (placebo 9.3%)
headache 12.2% (placebo 2.3%)
NCT00369577 · Phase 2 · registry result, not featured evidence
5 mg
sedation 13.3% (placebo 14%)
dizziness 11.1% (placebo 9.3%)
dysgeusia 4.4% (placebo 9.3%)
NCT00369577 · Phase 2 · registry result, not featured evidence
10 mg
dizziness 75% (placebo 35.7%)
dysgeusia 75% (placebo 0%)
somnolence 75% (placebo 21.4%)
NCT00444028 · Phase 1 · registry result, not featured evidence
5 mg
dizziness 57.1% (placebo 35.7%)
fatigue 42.9% (placebo 7.1%)
dysgeusia 28.6% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
2.5 mg
dizziness 50% (placebo 35.7%)
nausea 50% (placebo 0%)
dysgeusia 33.3% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
1.25 mg
dizziness 25% (placebo 35.7%)
dysgeusia 25% (placebo 0%)
headache 25% (placebo 14.3%)
NCT00444028 · Phase 1 · registry result, not featured evidence
0.625 mg
dizziness 28.6% (placebo 35.7%)
disturbance in attention 14.3% (placebo 7.1%)
dysgeusia 14.3% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 8.3 weeks versus 0.0119 weeks.
  5. eAssessment timepoints differ: 8 weeks versus 0.0119 weeks.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Asenapine

BPRS Total 7.72 score @ 2wk5 mg twice daily
absolute change · score
No placebo or comparator arm
NCT01549041 · Phase 4 · registry result, not featured evidence
show 1 more result
16.08 score @ 2wk10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
Time to Loss of Efficacy 5.82 months5/10 mg BID
time to event · months
Extension (open-label)
No placebo or comparator arm
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 177 days as posted
show 1 more result
12.09 months*5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 368 days as posted
PANSS Total -21.7 vs -16.2 placebo score @ 6wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 18 more results
-4.9 vs -4.8 placebo score @ 0.57wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-9.1 vs -7.1 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-12.5 vs -10.7 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-14.8 vs -13.2 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-17.1 vs -15.5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-19 vs -15.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-12.24 vs -0.95 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-25.5 vs -17.8 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-14.17 vs -0.95 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-17.4 vs -16.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.8 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.2 vs -7.1 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-9.9 vs -10.7 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-12 vs -13.2 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-12.3 vs -15.5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-17 vs -15.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-23.7 vs -17.8 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-21 vs -27.5 olanzapine score @ 52wk
NCT00212784 · Phase 3 · sponsor-reported, not registry data
CGI-S -1.2 vs -1 placebo score @ 6wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-0.2 vs -0.2 placebo score @ 0.57wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.3 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.5 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.7 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.8 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.1 vs -0.8 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.69 vs -0.18 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.3 vs -0.8 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-0.77 vs -0.18 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.9 vs -1 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.1 vs -0.2 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.3 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.5 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.7 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.8 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.1 vs -0.8 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS 30% 25.2% (n=111) vs 19.2% (n=99) placebo @ 6wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
0% (n=111) vs 2.1% (n=99) placebo @ 0.57wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 5.1% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 7.1% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
14.4% (n=111) vs 13.1% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
16.2% (n=111) vs 14.1% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
21.6% (n=111) vs 17.2% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49% (n=104) vs 36% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 51 participants as posted
72.1% (n=104) vs 62% (n=100) placebo @ 8.4wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
14.6% (n=96) vs 19.2% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0% (n=96) vs 2.1% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
2.1% (n=96) vs 5.1% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2% (n=96) vs 7.1% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.3% (n=96) vs 13.1% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
10.4% (n=96) vs 14.1% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
15.6% (n=96) vs 17.2% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
50% (n=96) vs 36% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 48 participants as posted
64.2% (n=96) vs 62% (n=100) placebo @ 8.4wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
Weight 1.3 vs 0.3 placebo kg @ 6wk5 mg BID
absolute change · kg
NCT01617187 · Phase 3 · registry result, not featured evidence
show 2 more results
1.3 vs 0.3 placebo kg @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0 vs 2.6 Olanzapine kg @ 26wk
NCT00145496 · Phase 3 · registry result, not featured evidence
PANSS Negative -0.5 vs -0.8 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-1.3 vs -1.1 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -1.8 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.3 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -3 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -2.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.72 vs -0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.27 vs -0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.1 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.6 vs -1.8 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.3 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -3 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -3.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS Positive -1.6 vs -1.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-2.8 vs -2.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3.7 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5 vs -4.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.7 vs -5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.5 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.2 vs -5.4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.31 vs -0.85 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.63 vs -0.85 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -3.7 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.1 vs -5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -5.5 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.6 vs -5.4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -2.7 vs -2.4 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-4.9 vs -3.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.2 vs -5.4 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.4 vs -6.7 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.2 vs -7.7 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-9.2 vs -7.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.1 vs -8 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.26 vs 0.19 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-11.5 vs -8.5 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-6.34 vs 0.19 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-2.2 vs -2.4 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.1 vs -5.4 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -6.7 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -7.7 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.8 vs -7.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.9 vs -8 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.9 vs -8.5 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -1.8 vs -2 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-2.9 vs -2.8 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.1 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.4 vs -5.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.6 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.7 vs -6.1 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.6 vs -6.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.78 vs -1.37 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-8.9 vs -6.1 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-5.03 vs -1.37 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.3 vs -2 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.8 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -4.1 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.5 vs -5.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.8 vs -5.6 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.1 vs -6.1 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.8 vs -6.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.9 vs -6.1 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative -0.8 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.9 vs -1.3 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.8 vs -2 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.2 vs -2.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.7 vs -4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.77 vs -0.41 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-5.3 vs -3.7 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-3.35 vs -0.41 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.7 vs -1.3 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -2 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.6 vs -2.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.9 vs -3.5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -3 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -3.7 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought -0.7 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.4 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -1.5 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -2.4 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -2.7 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.48 vs 0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.8 vs -3.4 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-2.85 vs 0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.3 vs -1.5 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.4 vs -2.4 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.7 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.4 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence

+ 32 further endpoints in the CSV export.

Loxapine (Adasuve)

PANSS-EC -8.6 vs -5.5 placebo score @ 0.0119wk10 mg
absolute change · score
NCT00628589 · Phase 3 · monotherapy
show 1 more result
-8.1 vs -5.5 placebo score @ 0.0119wk5 mg
NCT00628589 · Phase 3 · monotherapy
PANSS-EC -8.56 vs -4.98 placebo PANSS units @ 0.0119wk10 mg
absolute change · PANSS units
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
-6.71 vs -4.98 placebo PANSS units @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
BARS -2.02 vs -0.93 placebo score @ 0.0119wk10 mg
absolute change · score
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.53 vs -0.93 placebo score @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
CGI-I 2.28 vs 3.19 placebo CGI-I Units (7=worse, 1=better) @ 0.0119wk10 mg
absolute value · CGI-I Units (7=worse, 1=better)
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
2.53 vs 3.19 placebo CGI-I Units (7=worse, 1=better) @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence

Bipolar Disorder

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline

Asenapine

Marketed by AbbVie and partners

Approved in Bipolar Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Loxapine (Adasuve)

Marketed by Lee's Pharmaceutical and partners

Phase 3 in Bipolar Disordersmall molecule
Partial signal

NCT04148963 · Phase 3 · status unknown

This Phase 3 trial randomly assigned agitated adults with schizophrenia or bipolar disorder to inhaled loxapine or inhaled placebo under quadruple-blind conditions, using change in the PANSS-EC agitation scale at 2 hours as the primary endpoint. No results have been posted, so this remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

No aligned efficacy figure on record for this race.

Results for Bipolar Disorder

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Loxapine (Adasuve): registry results are on file for Bipolar Disorder, but their comparison mappings are not yet available.

Available safety results

Asenapine

Dropout rate
33.3%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
show 6 more results
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
25%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
show 6 more results
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
Serious AEs
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
show 6 more results
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
10 mg
hypoaesthesia oral 50%
dizziness 38.9%
dysgeusia 38.9%
NCT01206517 · Phase 1 · registry result, not featured evidence
show 2 more results
5 mg
dystonia 66.7%
dizziness 33.3%
nausea 33.3%
NCT01206517 · Phase 1 · registry result, not featured evidence
2.5 mg
sedation 33.3%
dysgeusia 16.7%
hypoaesthesia oral 16.7%
NCT01206517 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Loxapine (Adasuve)'s landscape